Critical Insights From Humana Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Humana (NYSE:HUM) has been analyzed by 16 analysts, showing a shift towards a more cautious stance with a significant number of ratings moving to 'Indifferent' in the last 30 days. The average 12-month price target has been adjusted to $461.5, down from $547.09, reflecting a 15.64% decline. Analysts from firms like Barclays, Wells Fargo, and Goldman Sachs have adjusted their price targets and ratings, indicating a varied outlook on Humana's financial health and market performance. Despite positive revenue growth of 17.93% as of December 31, 2023, concerns about Humana's market capitalization, net margin, ROE, ROA, and debt management persist.
March 06, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Humana's analyst ratings have become more cautious, with a notable decline in the average 12-month price target. Despite strong revenue growth, concerns about its financial health could impact investor sentiment.
The shift towards a more cautious stance by analysts, coupled with a significant reduction in the average 12-month price target, reflects growing concerns about Humana's financial health despite its revenue growth. This could lead to negative investor sentiment in the short term, potentially impacting the stock price negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100